Russian Federation
UDK 61 Медицина. Охрана здоровья
The publication considers a case of ovarian malignancy in a patient suffering from 11 years of overlap syndrome: a combination of progressive systemic sclerosis with dermatomyositis (antisynthetic syndrome). Timely recognition and treatment of cancer prevented an unfavorable outcome for this patient. At the same time, the termination of the basic anti-inflammatory therapy of systemic diseases (in this case, the cancellation of mycophenolate mofetil due to the lack of the drug in the pharmacy network of the city) led to a deterioration of the course of the disease, an aggravation of the clinical picture, which can create a so-called "vicious circle" of these pathologies.
: scleroderma, dermatomyositis, cross syndrome, autoimmune reactions, clinical case, oncological diseases, neoplasia, diagnosis, management tactics.
1. Procenko G.A. (2016) Paraneoplasticheskie sindromy v revmatologicheskoy praktike. Ukr. revmatol. zhurn., 63(1): 33-37
2. Guseva N.G. Sistemnaya sklerodermiya. V kn. Sigidin Ya.A., Guseva N.G., Ivanova M.M. Diffuznye bolezni soedinitel'noy tkani. Ruk. dlya vrachey. M.Medicina, 2004, 341-487.
3. Yablonska S., Blaszczyk M.. Scleromyositis: A Scleroderma/Polymyositis overlap syndrome. Clinic. Rheumatol., 1998, 17, 465-467
4. Guseva N.G. Sistemnaya sklerodermiya. M., Medicina, 1975, 271
5. Orlova E.V., Plieva L.R., Pyatilova P.M., Novosartyan M.G. Dermatomiozit: klinicheskiy sluchay i obzor literatury. RMZh. 2017; (11): 850-2.
6. Starovoytova M.N., Desinova O.V., Guseva N.G. Perekrestnye formy sistemnoy sklerodermii. Nauchno-prakticheskaya revmatologiya. 2007; 7: 53.
7. Sidorova L.L., Spasskaya A.A., Myasnikov G.V. i dr. (2010) Paraneoplasticheskiy sindrom. Revmatologicheskie maski onkologicheskih zabolevaniy. Therapia, 2(44): 24-28.
8. Chіpko T.M., Golovach І.Yu., Vel'ma І.V. ta іn. (2013) Sklerodermopodіbniy paraneoplastichniy sindrom u pacієnta z rakom shlunka: opis klіnіchnogo vipadku. Ukr. revmatol. zhurn., 52(2).
9. Guseva I.A., Desinova O.V, Starovoytova M.N. et al. HLA-DRB1 polymorphism in systemic sclerosis overlap-syndromes in russian population. Ann. Rheum.Dis., 2005,113
10. Antelava O.A., Nasonov E.L. (2013) Fenotipicheskie osobennosti i klinicheskaya neodnorodnost' antisintetaznogo sindroma. Sovrem. revmatologiya, 3: 41-46.
11. Sіrenko Yu.M., Procenko G.O., Boychuk N.S. (2014) Antisintetazniy sindrom: osoblivostі dіagnostiki ta lіkuvannya. Ukr. revmatol. zhurn., 56(2): 85-88.
12. Guseva N.G., Ahnazarova V.D. Perekrestnye sindromy mezhdu sistemnoy sklerodermiey i drugimi zabolevaniyami soedinitel'noy tkani. Ter.arhiv, 1974, 11, 70-78.
13. Smolen J.S., Steiner G. Mixed connective tissue disease. To be or not to be? Arthr. Rheum., 1998, 41, 5, 768-777.
14. Pileckyte M., Baliūnaite R., Tamulaitiene V. (2008) Paraneoplastic rheumatic syndromes. Medicina, 39(5): 443-447.
15. Rosenthal A.K., McLanghlin J.K., Linet M.S. et al. (1993) Scleroderma and malignancy: an epidemiologic study. Ann. Rheum. Dis., 52: 531-533.
16. Shah A., Rosen A. (2011) Cancer and systemic sclerosis: novel insights into pathogenesis and clinical implications. Curr. Opin. Rheumatol., 23: 530-535
17. Shah A., Rosen L.R. (2015b) Cancer and Scleroderma: A Paraneoplastic Disease with Implications for Malignancy Screening. Curr. Opin. Rheumatol., 27(6): 563-570.
18. Le Roy E.S., Black S.M., Fleishmajer R. et al. Scleroderma (Systemic Sclerosis): classification, subsets and pathogenesis. J. Rheumatol., 1988, 15, 202-205
19. Revmatologiya: nacional'noe rukovodstvo / pod red. E.L. Nasonova, V.A. Nasonovoy. - M.: GEOTAR-Media, 2008. - 720 s
20. Revmatologiya: klinicheskie rekomendacii / pod red. akad. RAMN E.L. Nasonova. - 2-e izd., ispr. i dop. - M.: GEOTAR-Media, 2010. - 752 s.
